ALK -Rearranged Non‐Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling

Malinda Itchins, et al., The Oncologist

This report underscores the importance of genetic analysis of serial biopsies to capture the dynamic therapeutic vulnerabilities within a patient’s tumor, while providing a perspective on the complexity of ALK tyrosine kinase inhibitor treatment sequencing.